guly
Forumer storico
no gurda hai mal interpretato io quello non lo posso vedere per i motivi passati non per questa situazione di tampa dove chiaramente nicox non c'entra nulla,mi riferisco al suo modo di comportarsi del passato.
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
no gurda hai mal interpretato io quello non lo posso vedere per i motivi passati non per questa situazione di tampa dove chiaramente nicox non c'entra nulla,mi riferisco al suo modo di comportarsi del passato.
PIZZODIGINO
Pacifico
Al di la di tutto, senza dubbio, la Nicox si può candidare come titolo più sfigato della borsa di Parigi.
17 anni di delusioni, sono davvero tanti.
Una cosa mi da sollievo: anche l'Inter era rimasta 17 anni senza vincere scudetti e poi, con l'aiuto della magistratura, ne ha vinti parecchi di fila, più una Champion; chissà che anche a noi succeda la stessa cosa, anche visto che Garufi è un interista sfegatato.
17 anni di delusioni, sono davvero tanti.
Una cosa mi da sollievo: anche l'Inter era rimasta 17 anni senza vincere scudetti e poi, con l'aiuto della magistratura, ne ha vinti parecchi di fila, più una Champion; chissà che anche a noi succeda la stessa cosa, anche visto che Garufi è un interista sfegatato.
guly
Forumer storico
hai capito vinti a tavolino sai che bella soddisfazione,pure interista il pallonaro,mamma mia allora ha anche un altro difetto.
da juventino non posso che avere un altro motivo di non simpatia verso di lui.Comunque caro pizzo al di la delle battute scherzose goditi MOLMED se le hai ancora in portafoglio,per me sono di grande consolazione in questo momento,mi fanno passare anche il dolore di essere rientrato (anche se in maniera leggera) su nicox.
viralic
Forumer storico
Il farmaco non ha pr
hai capito vinti a tavolino sai che bella soddisfazione,pure interista il pallonaro,mamma mia allora ha anche un altro difetto.
Caro Guly....ti ricordo che Molmed prima di farla salire a febbraio ultimo scorso l'hanno fatta andare al minimo storico di 0,22......un bello scherzetto agli azionisti.....a quest'ora senza quello scherzo di qualcuno molto vicino alla società il titolo sarebbe a 0,80/ 0.90 prezzo ipotizzato da molti post approvazioni strimvelis e tk....invece non è arrivata ancora a 0,60. Tenendo conto che aveva toccato 0,42 prima del crollo a 0,22 , si traduce in un 35% di plus. In ogni caso se vai al nasdaq ti trovi una marea di azioni che sono salite oltre il 100% da febbraio senza news.....se Molmed fosse stata al nasdaq a quest'ora era ben sopra 1 euro.
viralic
Forumer storico
22 September, 2016
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced its financial results for the six months ended June 30, 2016, and provided an update on its activities.
“Following the recently completed transaction with GHO Capital involving our European and International commercial assets, we are now well positioned to refocus our resources on our promising R&D pipeline as we await FDA approval decisions for latanoprostene bunod and AC-170” commented Michele Garufi, Chairman and Chief Executive Officer of Nicox.“This transaction allows us to reduce our infrastructure costs by €6 million (approximately 66%) and, together with the recent financing of €18 million, to accelerate the development of our proprietary pipeline assets, including obtaining clinical proof-of-concept data for NCX 4251 and NCX 470 by the end of 2018.”
Quindi sino a fine 2018 hanno cassa sufficiente senza far altri ak........mi sarebbe piaciuto che Molmed avesse fatto altrettanto, invece la risposta della Villa è stata sibillina.....se akci sarà verrà comunicato come da regolamento entro i termini di legge agli azionisti.......aspettati un ak a cavallo dell'anno vecchio con quello nuovo e una discesa tra il 20 e il 30% .....
Sophia Antipolis, France.
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced its financial results for the six months ended June 30, 2016, and provided an update on its activities.
“Following the recently completed transaction with GHO Capital involving our European and International commercial assets, we are now well positioned to refocus our resources on our promising R&D pipeline as we await FDA approval decisions for latanoprostene bunod and AC-170” commented Michele Garufi, Chairman and Chief Executive Officer of Nicox.“This transaction allows us to reduce our infrastructure costs by €6 million (approximately 66%) and, together with the recent financing of €18 million, to accelerate the development of our proprietary pipeline assets, including obtaining clinical proof-of-concept data for NCX 4251 and NCX 470 by the end of 2018.”
Quindi sino a fine 2018 hanno cassa sufficiente senza far altri ak........mi sarebbe piaciuto che Molmed avesse fatto altrettanto, invece la risposta della Villa è stata sibillina.....se akci sarà verrà comunicato come da regolamento entro i termini di legge agli azionisti.......aspettati un ak a cavallo dell'anno vecchio con quello nuovo e una discesa tra il 20 e il 30% .....
viralic
Forumer storico
Nicox : Informations financières et point d’activité du premier semestre 2016
- Bausch + Lomb, partenaire licencié de Nicox pour le latanoprostene bunod, a reçu une lettre de réponse (Complete Response Letter) de la FDA américaine concernant son usine de fabrication ; aucun commentaire quant à l’efficacité ou à la sécurité du produit et aucune étude clinique supplémentaire requise pour une autorisation de mise sur le marché
- Revue prioritaire en cours par la FDA du dossier de demande d’autorisation de mise sur le marché (NDA) de l’AC-170
- Trésorerie de 34 millions d’euros ; Nicox bénéficie ainsi des ressources financières suffisantes pour finaliser d’ici fin 2018 ses études cliniques de preuve de concept pour les produits de son portefeuille NCX 4251 et NCX 470
- Le recentrage en Recherche et Développement uniquement permettra une réduction significative des charges opérationnelles
PIZZODIGINO
Pacifico
Nicox first half 2016 business and financial update
22 September 2016
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced its financial results for the six months ended June 30, 2016, and provided an update on its activities.
“Following the recently completed transaction with GHO Capital involving our European and International commercial assets, we are now well positioned to refocus our resources on our promising R&D pipeline as we await FDA approval decisions for latanoprostene bunod and AC-170” commented Michele Garufi, Chairman and Chief Executive Officer of Nicox. “This transaction allows us to reduce our infrastructure costs by €6 million (approximately 66%) and, together with the recent financing of €18 million, to accelerate the development of our proprietary pipeline assets, including obtaining clinical proof-of-concept data for NCX 4251 and NCX 470 by the end of 2018.”
Operational highlights for the six months to June 30, 2016 and post-reporting period
• Philippe Masquida, EVP, Managing Director European & International Operations, will be leaving the company at the end of September 2016, following the successful completion of the transfer of the European and International commercial operations. Nicox sincerely thanks Philippe for his years of service and his significant contributions to the commercial business.
First-half financial summary2
The Group’s revenues have been retreated following reclassification of the European commercial business as Discontinued Operations. For information, the European and International product sales of the operations transferred to VISUfarma BV, the new Group led by GHO Capital, were €7.1 million over the first half of 2016, an increase of 50% compared to the same period in 2015.
Excluding Discontinued Operations the operating expenses for the period were €12.0 million compared to €8.8 million for the six months to June 2015. The increase in operating expenses over the period is mainly explained by costs related to the submission of the AC-170 NDA.
Excluding the Discontinued Operations, the Group recorded a net loss of €12.3 million as of June 2016, compared to a net loss of €10.1 million3 at the same date in 2015.
The Group had cash, cash equivalents and financial instruments of €12.3 million as of June 30, 2016, compared to €29 million on December 31, 2015; however, considering the financing in July of this year of €18 million gross and the €8.9 million cash payment following the transfer of the European commercial operations to VISUfarma BV, our unaudited cash, cash equivalents and financial instruments at August 31, 2016 are estimated at €34.1 million.
The half-yearly financial report will be available in French by the end of September 2016 on Nicox’s website www.nicox.com in the section Investor Information > Regulated information > Financial Information.
The procedures relating to the limited review of the interim financial statements have been carried out. The limited review report will be issued after the finalisation of the procedures required for the publication of the-first half financial report
22 September 2016
- Latanoprostene bunod licensee Bausch + Lomb receives Complete Response Letter from U.S. FDA pertaining to B+L manufacturing facility; no efficacy or safety concerns or additional clinical trials regarding the compound identified for approva
- AC-170 NDA under FDA Priority Review approval process
- Cash position of €34.1 million1: Nicox sufficiently financed through completion of clinical proof-of-concept trials for pipeline assets NCX 4251 and NCX 470 by end of 2018
- Refocusing on R&D-only allows significant reduction in operating costs going forward
Sophia Antipolis, France
Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced its financial results for the six months ended June 30, 2016, and provided an update on its activities.
“Following the recently completed transaction with GHO Capital involving our European and International commercial assets, we are now well positioned to refocus our resources on our promising R&D pipeline as we await FDA approval decisions for latanoprostene bunod and AC-170” commented Michele Garufi, Chairman and Chief Executive Officer of Nicox. “This transaction allows us to reduce our infrastructure costs by €6 million (approximately 66%) and, together with the recent financing of €18 million, to accelerate the development of our proprietary pipeline assets, including obtaining clinical proof-of-concept data for NCX 4251 and NCX 470 by the end of 2018.”
Operational highlights for the six months to June 30, 2016 and post-reporting period
- In August 2016, Nicox completed the transfer of its European and International commercial operations to a new pan-European ophthalmic specialty pharmaceutical company led by GHO Capital. The transaction was valued at up to €26 million and the Company received a €9 million upfront cash payment upon closing of the transaction and a minority stake in the new company.
- In July 2016, Nicox completed a financing through a reserved capital increase of ordinary shares of the Company with a specific category of investors. Gross proceeds from the financing were €18 million.
- On July 21, 2016, latanoprostene bunod licensee Bausch + Lomb (a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.) announced its receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the use of latanoprostene bunod for the treatment of glaucoma. The CRL cited concerns pertaining to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb’s manufacturing facility in Tampa, Florida. The FDA’s letter did not identify any efficacy or safety concerns with respect to the latanoprostene bunod NDA or additional clinical trials needed for the approval of the NDA. Bausch + Lomb is currently working with the FDA to resolve and address the CGMP concerns. Latanoprostene bunod has the potential to generate significant revenue for Nicox through milestones (up to $132.5 million net, mainly on commercial sales targets) and royalties (potential net tiered royalties on sales from 6% to 11%).
- In June, Nicox announced that the U.S. FDA had accepted the Company’s NDA for AC-170, a novel, proprietary eye drop formulation of cetirizine, targeting the treatment of ocular itching associated with allergic conjunctivitis. The FDA also granted Priority Review and assigned a Prescription Drug User Fee (PDUFA) goal date of October 18, 2016 (contingent upon the information and data provided by Nicox during the review period). Approval of the AC-170 NDA prior to December 1st, 2016 will trigger a milestone payment of $35 million in Nicox shares to former Aciex shareholders or $10 million in Nicox shares if approval of the NDA is received after this date. Nicox is currently in partnering discussions in the United States for this program.
• Philippe Masquida, EVP, Managing Director European & International Operations, will be leaving the company at the end of September 2016, following the successful completion of the transfer of the European and International commercial operations. Nicox sincerely thanks Philippe for his years of service and his significant contributions to the commercial business.
First-half financial summary2
The Group’s revenues have been retreated following reclassification of the European commercial business as Discontinued Operations. For information, the European and International product sales of the operations transferred to VISUfarma BV, the new Group led by GHO Capital, were €7.1 million over the first half of 2016, an increase of 50% compared to the same period in 2015.
Excluding Discontinued Operations the operating expenses for the period were €12.0 million compared to €8.8 million for the six months to June 2015. The increase in operating expenses over the period is mainly explained by costs related to the submission of the AC-170 NDA.
Excluding the Discontinued Operations, the Group recorded a net loss of €12.3 million as of June 2016, compared to a net loss of €10.1 million3 at the same date in 2015.
The Group had cash, cash equivalents and financial instruments of €12.3 million as of June 30, 2016, compared to €29 million on December 31, 2015; however, considering the financing in July of this year of €18 million gross and the €8.9 million cash payment following the transfer of the European commercial operations to VISUfarma BV, our unaudited cash, cash equivalents and financial instruments at August 31, 2016 are estimated at €34.1 million.
The half-yearly financial report will be available in French by the end of September 2016 on Nicox’s website www.nicox.com in the section Investor Information > Regulated information > Financial Information.
The procedures relating to the limited review of the interim financial statements have been carried out. The limited review report will be issued after the finalisation of the procedures required for the publication of the-first half financial report
PIZZODIGINO
Pacifico
Abbiamo cassa sino alla fine del 2018, non male direi, perché per allora il Vyzulta sarà sul mercato e noi incasseremo le royalties.
guly
Forumer storico
senti questo discorso vale anche per nicox l'hanno portata ai minimi a 0,80 (mi sembra) e poi e' risalita grazie alla speculazione sull'attesa del bunod e nel frattempo il tuo amico pallonaro ha fatto un adc che aveva sempre negato (invece sui forum di boursorama si paventava ma tu dicesti che il apllonaro era incazzato me minacciava querele a ci affermava cio').
Sul discorso di molmed si hanno fatto un adc ma per i piccoli azionisti (almeno per me) e' stato molto ma molto positivo.
Lasciamo perdere il discorso del nasdaq perche' e' ridicolo metterlo in campo,si sa benissimo che li' e' un altro mondo nel bene e nel male e anche il comportamento di nicox chiramente sarebbe stato diverso.
guly
Forumer storico
e difatti il mercato ha preso proprio bene questi numeri un -3 e rotti con volumi triplicati.l'AK di molmed?guarda tu sull'altro forum ripetevi in continuazione di questo ak e che molmed sarebbe di nuovo miseramente ricrollata sotto 0,42,hai sputtanato Palmisano definendolo un fruttivendolo e molmed un cesso che vende solo due ortaggi prendendo un grosso abbaglio (le definizioni di Palmisano le dovresti rivolgere a ben altri soggetti visti i risultati ottenuti da uno in pochi mesi e da un altro in tantissimi anni)
Comunque sai a questi prezzi,e forse anche piu' in alto,un adc lo sottoscriverei volentieri viste le prospettive che si sono aperte per molmed.
Cosa che non farei di certo per nicox.
